OMNIAB, INC. (OABI) Spending and interest coverage
- R&D / revenue · 12 months: Value 113.15%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 36.58%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 113.15% | Research and development expense / revenue. Period ending 2026-06-30. $43.51M ÷ $38.46M × 100 ≈ 113.15% |
| Stock-based compensation / revenue · 12 months | 36.58% | Share-based compensation / revenue. Period ending 2026-06-30. $14.07M ÷ $38.46M × 100 ≈ 36.58% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 43.51M USD | Research and Development Expense |
| Revenue | 38.46M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 14.07M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -48.37M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $43.51M | $38.46M | $14.07M | $-48.37M | (m) | 113.15% | 36.58% | (m) | (m) |
| 2026-03-31 | $44.79M | $28.94M | $15.02M | $-57.95M | (m) | 154.78% | 51.90% | (m) | (m) |
| 2025-12-31 | $47.75M | $18.67M | $15.82M | $-68.97M | (m) | 255.83% | 84.77% | (m) | (m) |
| 2025-09-30 | $47.15M | $21.09M | $17.33M | $-69.08M | (m) | 223.53% | 82.18% | (m) | (m) |
| 2025-06-30 | $50.09M | $23.03M | $18.68M | $-70.71M | (m) | 217.53% | 81.10% | (m) | (m) |
| 2025-03-31 | $53.16M | $26.74M | $19.95M | $-70.79M | (m) | 198.78% | 74.59% | (m) | (m) |
| 2024-12-31 | $55.11M | $26.39M | $21.50M | $-74.50M | (m) | 208.82% | 81.46% | (m) | (m) |
| 2024-09-30 | $56.57M | $20.41M | $22.31M | $-79.83M | (m) | 277.18% | 109.31% | (m) | (m) |
| 2024-06-30 | $57.12M | $21.71M | $23.31M | $-80.38M | (m) | 263.05% | 107.37% | (m) | (m) |
| 2024-03-31 | $57.32M | $21.05M | $24.46M | $-83.52M | (m) | 272.34% | 116.22% | (m) | (m) |
| 2023-12-31 | $56.52M | $34.16M | $24.82M | $-69.42M | (m) | 165.45% | 72.65% | (m) | (m) |
| 2023-09-30 | $54.68M | $64.69M | $24.94M | $-39.16M | (m) | 84.53% | 38.56% | (m) | (m) |
| 2023-06-30 | $54.00M | $66.12M | $23.91M | $-33.76M | (m) | 81.67% | 36.16% | (m) | (m) |
| 2023-03-31 | $51.35M | $66.37M | $21.23M | $-26.88M | (m) | 77.37% | 31.99% | (m) | (m) |
| 2022-12-31 | $48.36M | $59.08M | $18.32M | $-26.65M | $0.00 | 81.87% | 31.01% | (m) | Reported |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $39.23M | $34.75M | $15.06M | $-35.61M | $7.00K | 112.90% | 43.36% | -5087.00× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |